392 related articles for article (PubMed ID: 21339642)
1. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
[TBL] [Abstract][Full Text] [Related]
2. Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome.
Yin JC; Platt MJ; Tian X; Wu X; Backx PH; Simpson JA; Araki T; Neel BG
Nat Commun; 2017 May; 8():15518. PubMed ID: 28548091
[TBL] [Abstract][Full Text] [Related]
3. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
[TBL] [Abstract][Full Text] [Related]
4. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.
Passariello CL; Martinez EC; Thakur H; Cesareo M; Li J; Kapiloff MS
J Mol Cell Cardiol; 2016 Apr; 93():98-105. PubMed ID: 26940993
[TBL] [Abstract][Full Text] [Related]
5. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.
Wu X; Yin J; Simpson J; Kim KH; Gu S; Hong JH; Bayliss P; Backx PH; Neel BG; Araki T
Mol Cell Biol; 2012 Oct; 32(19):3872-90. PubMed ID: 22826437
[TBL] [Abstract][Full Text] [Related]
6. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.
Dhandapany PS; Fabris F; Tonk R; Illaste A; Karakikes I; Sorourian M; Sheng J; Hajjar RJ; Tartaglia M; Sobie EA; Lebeche D; Gelb BD
J Mol Cell Cardiol; 2011 Jul; 51(1):4-15. PubMed ID: 21440552
[TBL] [Abstract][Full Text] [Related]
9. Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues.
Nakhaei-Rad S; Haghighi F; Bazgir F; Dahlmann J; Busley AV; Buchholzer M; Kleemann K; Schänzer A; Borchardt A; Hahn A; Kötter S; Schanze D; Anand R; Funk F; Kronenbitter AV; Scheller J; Piekorz RP; Reichert AS; Volleth M; Wolf MJ; Cirstea IC; Gelb BD; Tartaglia M; Schmitt JP; Krüger M; Kutschka I; Cyganek L; Zenker M; Kensah G; Ahmadian MR
Commun Biol; 2023 Jun; 6(1):657. PubMed ID: 37344639
[TBL] [Abstract][Full Text] [Related]
10. MEK Inhibition in a Newborn with
Mussa A; Carli D; Giorgio E; Villar AM; Cardaropoli S; Carbonara C; Campagnoli MF; Galletto P; Palumbo M; Olivieri S; Isella C; Andelfinger G; Tartaglia M; Botta G; Brusco A; Medico E; Ferrero GB
Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052347
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
Kobayashi T; Aoki Y; Niihori T; Cavé H; Verloes A; Okamoto N; Kawame H; Fujiwara I; Takada F; Ohata T; Sakazume S; Ando T; Nakagawa N; Lapunzina P; Meneses AG; Gillessen-Kaesbach G; Wieczorek D; Kurosawa K; Mizuno S; Ohashi H; David A; Philip N; Guliyeva A; Narumi Y; Kure S; Tsuchiya S; Matsubara Y
Hum Mutat; 2010 Mar; 31(3):284-94. PubMed ID: 20052757
[TBL] [Abstract][Full Text] [Related]
12. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
[TBL] [Abstract][Full Text] [Related]
13. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
Razzaque MA; Nishizawa T; Komoike Y; Yagi H; Furutani M; Amo R; Kamisago M; Momma K; Katayama H; Nakagawa M; Fujiwara Y; Matsushima M; Mizuno K; Tokuyama M; Hirota H; Muneuchi J; Higashinakagawa T; Matsuoka R
Nat Genet; 2007 Aug; 39(8):1013-7. PubMed ID: 17603482
[TBL] [Abstract][Full Text] [Related]
14. RAF1 mutation leading to hypertrophic cardiomyopathy in a Chinese family with a history of sudden cardiac death: A diagnostic insight into Noonan syndrome.
Zheng J; Peng L; Cheng R; Li Z; Xie J; Huang E; Cheng J; Zhao Q
Mol Genet Genomic Med; 2024 Jan; 12(1):e2290. PubMed ID: 37787490
[TBL] [Abstract][Full Text] [Related]
15. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.
Chen PC; Wakimoto H; Conner D; Araki T; Yuan T; Roberts A; Seidman C; Bronson R; Neel B; Seidman JG; Kucherlapati R
J Clin Invest; 2010 Dec; 120(12):4353-65. PubMed ID: 21041952
[TBL] [Abstract][Full Text] [Related]
16. PHENOTYPIC CONSEQUENCES AND THE MALIGNANCY RISK IN FAMILIAL NOONAN SYNDROME DUE TO A RARE P.S427G RAF1 MUTATION.
Pelc M; Ciara E; Jezela-Stanek A; Krajewska-Walasek M
Genet Couns; 2016; 27(3):325-333. PubMed ID: 30204961
[TBL] [Abstract][Full Text] [Related]
17. Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases with a specific RAF1 mutation.
Hopper RK; Feinstein JA; Manning MA; Benitz W; Hudgins L
Am J Med Genet A; 2015 Apr; 167A(4):882-5. PubMed ID: 25706034
[TBL] [Abstract][Full Text] [Related]
18. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
[TBL] [Abstract][Full Text] [Related]
19. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
[TBL] [Abstract][Full Text] [Related]
20. K-RasV14I recapitulates Noonan syndrome in mice.
Hernández-Porras I; Fabbiano S; Schuhmacher AJ; Aicher A; Cañamero M; Cámara JA; Cussó L; Desco M; Heeschen C; Mulero F; Bustelo XR; Guerra C; Barbacid M
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16395-400. PubMed ID: 25359213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
